Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | CLTC | Q00610 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | BRD1 | O95696 | 1/20 | 0.50 |
| ▸ | TAF1 | P21675 | 1/20 | 0.50 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163766 | 0.86 | CYP2C9 (0.57) | CYP2C9CYP2C19MPOCLTCL3MBTL1 | |
| SCHEMBL5159234 | 0.86 | MPO (0.59) | MPOCLTCBRD1TAF1BRPF1 | |
| SCHEMBL5162692 | 0.83 | CLTC (0.76) | CYP2C9CYP2C19CLTCL3MBTL1CA12 | |
| SCHEMBL5160278 | 0.82 | CYP2C9 (0.55) | CYP2C9CYP2C19CLTCL3MBTL1CA12 | |
| SCHEMBL14510297 | 0.81 | KMT2A (0.59) | CYP2C9CYP2C19MPOCLTCL3MBTL1 | |
| SCHEMBL28763787 | 0.80 | ALDH1A1 (0.61) | CA12CA9POLBMEN1KMT2A | |
| SCHEMBL29549870 | 0.80 | ALDH1A1 (0.61) | CA12CA9POLBMEN1KMT2A | |
| SCHEMBL14510363 | 0.77 | CYP2C9 (0.63) | CYP2C9CYP2C19CLTCL3MBTL1CA12 | |
| SCHEMBL5153048 | 0.77 | CYP2C9 (0.46) | CYP2C9CYP2C19MPOCLTCL3MBTL1 | |
| SCHEMBL5528588 | 0.75 | CLTC (0.77) | CYP2C9CYP2C19CLTCL3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | claimed |
| WO-2007030939-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| WO-2007030939-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | CYP2C9 4879/4885CYP2C19 4871/4885MPO 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.